论文部分内容阅读
山东省医药工业研究所生产的格列齐特片(GZ,又称达美康)是治疗糖尿病(DM)的良药。现将其基础研究概述如下。 1.药代动力学:GZ口服后3～4小时血浓度达高峰,血浆蛋白结合率为92％,半衰期约12小时,主要在肝脏代谢,大多从尿中排泄,原形不到1％,故不引起持久性低血糖。但在肝肾功能严重衰竭时有可能引起药物积蓄,故被列为禁忌症。 2.药效学:①降血糖:实验表明,GZ可使正常动物血糖明显下降,并在一定范围内与剂量密切相关。
Shandong Province Institute of Pharmaceutical Industry Gliclazide tablets (GZ, also known as daramecon) is the treatment of diabetes mellitus (DM) medicine. The basic research is summarized as follows. 1. Pharmacokinetics: GZ oral concentration of 3 to 4 hours after the peak blood concentration, plasma protein binding rate of 92%, half-life of about 12 hours, mainly in the liver metabolism, mostly excreted from the urine, the prototype less than 1%, so the Does not cause persistent hypoglycemia. However, serious failure of liver and kidney function may lead to drug accumulation, it is classified as contraindications. 2. Pharmacodynamics: ① hypoglycemic: Experiments show that, GZ can make the normal animal blood glucose decreased significantly, and within a certain range and dosage are closely related.